0Q1G Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$540.00 |
52 Week High | US$540.00 |
52 Week Low | US$540.00 |
Beta | 0.32 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 3,461.00% |
Recent News & Updates
Recent updates
Shareholder Returns
0Q1G | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0% | -2.0% | -0.01% |
1Y | n/a | -4.9% | 0.8% |
Return vs Industry: Insufficient data to determine how 0Q1G performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0Q1G performed against the UK Market.
Price Volatility
0Q1G volatility | |
---|---|
0Q1G Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 8.5% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Q1G has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0Q1G's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | https://www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
0Q1G fundamental statistics | |
---|---|
Market cap | CHF610.39b |
Earnings (TTM) | CHF4.62b |
Revenue (TTM) | CHF30.07b |
132.2x
P/E Ratio20.3x
P/S RatioIs 0Q1G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0Q1G income statement (TTM) | |
---|---|
Revenue | US$34.12b |
Cost of Revenue | US$7.08b |
Gross Profit | US$27.04b |
Other Expenses | US$21.80b |
Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 5.82 |
Gross Margin | 79.25% |
Net Profit Margin | 15.36% |
Debt/Equity Ratio | 233.4% |
How did 0Q1G perform over the long term?
See historical performance and comparison